TXA
Tranexamic acid, a medication that reduces excessive bleeding by stabilizing formed clots, used in trauma resuscitation when administered within hours of injury.
In the Field
TXA is one of the more significant additions to trauma medicine in the past fifteen years. The drug works by preventing the body from breaking down clots faster than it can form them, which is exactly what happens in major trauma. The catch is timing: TXA helps when given early and may actually harm when given late. The three-hour window from injury is the doctrinal cutoff. For tactical medics operating in austere or extended evacuation environments, TXA has moved from a hospital intervention to a forward-deployed one, and aid bag specifications now reflect that.
Common Mistake
Administering TXA outside the established three-hour post-injury window, or carrying it in agencies where the medical director protocol does not authorize its use.
Technical Detail
Tranexamic Acid (TXA) is a synthetic medication that inhibits the breakdown of fibrin, the protein matrix that forms the structural component of blood clots. Mechanistically, TXA blocks the conversion of plasminogen to plasmin, preventing the enzymatic dissolution of formed clots. Clinically, TXA helps the body retain clots that have already formed in response to bleeding, reducing the overall blood loss in trauma.
Evidence base. The CRASH-2 trial, published in 2010, established TXA as a significant intervention in trauma resuscitation. The study, which enrolled over 20,000 trauma patients, showed reduced all-cause mortality in patients receiving TXA within three hours of injury. Subsequent military trauma research, civilian trauma analyses, and the CRASH-3 trial (focused on traumatic brain injury) have refined understanding of TXA's role.
The three-hour window. TXA's mortality benefit is time-dependent. The strongest benefit is observed when administered within one hour of injury. Benefit persists when administered within three hours. Administration after three hours has not shown mortality benefit and, in some studies, has been associated with increased mortality, possibly due to interference with the body's transition from clot formation to clot resolution. The three-hour cutoff is a doctrinal limit in current trauma protocols.
Indications. TXA is indicated for trauma patients with significant hemorrhage or at risk of significant hemorrhage. Specific indications vary by protocol but commonly include:
Trauma patients with systolic blood pressure below 90 mmHg or signs of hemorrhagic shock.
Trauma patients with active major bleeding.
Suspected internal hemorrhage from blunt or penetrating trauma.
Traumatic brain injury with positive imaging findings or significant mechanism of injury (per CRASH-3 evidence).
Dosing. The standard adult dose is 1 gram administered intravenously over 10 minutes, followed by 1 gram administered intravenously over 8 hours. In tactical and prehospital settings, the initial bolus is the relevant administration; the maintenance infusion is typically delivered at the receiving facility.
Field deployment. TXA was historically a hospital-based intervention but has progressively moved forward in trauma care:
Military deployment. The U.S. military adopted TXA in forward-deployed medical units in the early 2010s, with TXA carried by tactical medics and administered en route to higher levels of care.
Civilian tactical medicine. Civilian tactical paramedic programs have increasingly added TXA where state EMS protocols and service medical director authority permit.
Air medical and ground EMS. Many advanced civilian EMS services now carry TXA as a standard ALS medication for trauma response.
Aid bag specifications. TXA appears in advanced aid bag specifications for tactical paramedics, SWAT medics, and prolonged field care providers. The drug is supplied as a single-dose vial requiring IV access for administration. Carrying TXA requires:
State EMS scope of practice authorization for the provider.
Service medical director protocol approval.
IV administration capability and supplies.
Storage compliance with manufacturer requirements.
For agencies considering adding TXA to their tactical medical loadout, the procurement decision involves drug cost, training, scope of practice review, and protocol development with the medical director. The drug itself is relatively inexpensive; the operational integration is the larger investment.
Lethal Triad relevance. TXA's role in trauma resuscitation directly addresses one component of the Lethal Triad and Lethal Diamond models. By stabilizing formed clots, TXA mitigates one mechanism of trauma-induced coagulopathy, supporting the body's ability to maintain hemostasis during ongoing hemorrhage.
RELATED TERMS:
Evidence base. The CRASH-2 trial, published in 2010, established TXA as a significant intervention in trauma resuscitation. The study, which enrolled over 20,000 trauma patients, showed reduced all-cause mortality in patients receiving TXA within three hours of injury. Subsequent military trauma research, civilian trauma analyses, and the CRASH-3 trial (focused on traumatic brain injury) have refined understanding of TXA's role.
The three-hour window. TXA's mortality benefit is time-dependent. The strongest benefit is observed when administered within one hour of injury. Benefit persists when administered within three hours. Administration after three hours has not shown mortality benefit and, in some studies, has been associated with increased mortality, possibly due to interference with the body's transition from clot formation to clot resolution. The three-hour cutoff is a doctrinal limit in current trauma protocols.
Indications. TXA is indicated for trauma patients with significant hemorrhage or at risk of significant hemorrhage. Specific indications vary by protocol but commonly include:
Trauma patients with systolic blood pressure below 90 mmHg or signs of hemorrhagic shock.
Trauma patients with active major bleeding.
Suspected internal hemorrhage from blunt or penetrating trauma.
Traumatic brain injury with positive imaging findings or significant mechanism of injury (per CRASH-3 evidence).
Dosing. The standard adult dose is 1 gram administered intravenously over 10 minutes, followed by 1 gram administered intravenously over 8 hours. In tactical and prehospital settings, the initial bolus is the relevant administration; the maintenance infusion is typically delivered at the receiving facility.
Field deployment. TXA was historically a hospital-based intervention but has progressively moved forward in trauma care:
Military deployment. The U.S. military adopted TXA in forward-deployed medical units in the early 2010s, with TXA carried by tactical medics and administered en route to higher levels of care.
Civilian tactical medicine. Civilian tactical paramedic programs have increasingly added TXA where state EMS protocols and service medical director authority permit.
Air medical and ground EMS. Many advanced civilian EMS services now carry TXA as a standard ALS medication for trauma response.
Aid bag specifications. TXA appears in advanced aid bag specifications for tactical paramedics, SWAT medics, and prolonged field care providers. The drug is supplied as a single-dose vial requiring IV access for administration. Carrying TXA requires:
State EMS scope of practice authorization for the provider.
Service medical director protocol approval.
IV administration capability and supplies.
Storage compliance with manufacturer requirements.
For agencies considering adding TXA to their tactical medical loadout, the procurement decision involves drug cost, training, scope of practice review, and protocol development with the medical director. The drug itself is relatively inexpensive; the operational integration is the larger investment.
Lethal Triad relevance. TXA's role in trauma resuscitation directly addresses one component of the Lethal Triad and Lethal Diamond models. By stabilizing formed clots, TXA mitigates one mechanism of trauma-induced coagulopathy, supporting the body's ability to maintain hemostasis during ongoing hemorrhage.
RELATED TERMS: